- Home
- NBR vs IMCR Comparison
NBR vs IMCR Comparison
Compare NBR & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBR | IMCR |
|---|---|---|
| Founded | 1952 | 2008 |
| Country | Bermuda | United Kingdom |
| Employees | 13900 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.4B |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | NBR | IMCR |
|---|---|---|
| Price | $86.70 | $28.60 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 7 | 10 |
| Target Price | ★ $75.00 | $66.33 |
| AVG Volume (30 Days) | 255.4K | ★ 443.4K |
| Earning Date | 04-28-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 30.39 |
| EPS | N/A | ★ 0.25 |
| Revenue | N/A | ★ $249,428,000.00 |
| Revenue This Year | $3.65 | $14.57 |
| Revenue Next Year | $4.88 | $8.21 |
| P/E Ratio | ★ $4.33 | $114.36 |
| Revenue Growth | N/A | ★ 43.05 |
| 52 Week Low | $27.33 | $27.56 |
| 52 Week High | $112.90 | $40.71 |
Technical Indicators
Market Signals| Indicator | NBR | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 37.73 | 48.22 |
| Support Level | $75.43 | $27.66 |
| Resistance Level | $92.38 | $31.56 |
| Average True Range (ATR) | 5.01 | 1.21 |
| MACD | -1.50 | 0.04 |
| Stochastic Oscillator | 15.75 | 45.95 |
Price Performance
Historical ComparisonAbout NBR Nabors Industries Ltd.
Nabors Industries Ltd owns and operates land-based drilling rig fleets and is a provider of offshore platform rigs in the United States and international markets. It also provides performance tools, directional drilling services, tubular running services, and technologies. The company has four reportable segments: U.S. Drilling, International Drilling, Drilling Solutions, and Rig Technologies. The key revenue of the company is generated from International Drilling.
About IMCR Immunocore Holdings plc
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.